Textbook of Personalized Medicine - Second Edition [2015]

325 generally consume higher levels of folate than normal cells to fuel their growth, some cancer cell types, including ovarian, ...

326 own, though they did correspond to better oropharyngeal cancer survival when found together with positive blood tests for E6 ...

327 mutation leading to a tyrosine kinase deregulation would make a suitable target for the development of specifi c therapies. ...

328 are much lower than the standard regimen. Physicians at St. Jude’s Children’s Hospital (Memphis, TN) and at the Mayo Clinic ...

329 American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend testing for the FLT3 mutation, ...

330 of Bcl-2 family proteins to address clinical response to cytarabine-based therapy in patients with AML (Pierceall et al. 201 ...

331 Personalized Management of Chronic Lymphocytic Leukemia Chronic lymphocytic leukemia (CLL) is the most common leukemia in th ...

332 may be more effi cacious. Furthermore, TK inhibitor-mediated molecular response provides valuable risk stratifi cation and p ...

333 ments tailored to a patient’s specifi c form of the disease and also narrow down areas of the chromosomes in myeloma cells l ...

334 Personalized Management of Myelodysplastic Syndrome Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disor ...

335 multiply uncontrollably, causing B cell lymphomas. A gene called BCL6 codes for a protein, which is a transcriptional repres ...

336 Personalized Vaccine for Follicular Lymphoma Follicular lymphoma is considered incurable, although cyclophosphamide, doxoru- ...

337 Personalized Management of Gastrointestinal Cancer Personalized Management of Esophageal Cancer Esophageal cancer is highly ...

338 Several molecular therapies are in development for gastric cancer. Cyclooxygenase-2 (COX-2) is overexpressed in and correlat ...

339 et al. 2009 ). The model included a cancer-negative sigmoidoscopy/colonoscopy in the last 10 years, polyp history in the las ...

340 regimens. For this reason the development and application of individualized therapy has been the goal of several studies wit ...

341 Oncotype DX ® Recurrence Score ® test as well as T-stage and mismatch repair sta- tus, should be considered during the treat ...

342 Caraglia 2009 ). Additional investigation is needed to validate the clinical relevance of individual genetic differences. In ...

343 genomic changes and their signifi cance for CRC tumorigenesis was lacking. Genomic patterns that have now been uncovered in ...

344 Systems Biology Approach to Drug Resistance in Colorectal Cancer Mechanisms that may have important implications for drug ef ...